Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis

Clyve Yu Leon Yaow; Han Jie Lee; Seth En Teoh; Ryan Ian Houe Chong; Tze Kiat Ng; Kae Jack Tay; Henry Ho; Yan Mee Law; Jeffrey Tuan; John Yuen; Kenneth Chen

doi:10.1016/j.euo.2023.09.002

Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis

Eur Urol Oncol. 2023 Sep 18:S2588-9311(23)00175-X. doi: 10.1016/j.euo.2023.09.002. Online ahead of print.

Authors

Affiliations

¹ Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
² Department of Urology, Singapore General Hospital, Singapore.
³ Department of Diagnostic Radiology, Singapore General Hospital, Singapore.
⁴ Department of Radiation Oncology, National Cancer Centre Singapore, Singapore.
⁵ Department of Urology, Singapore General Hospital, Singapore. Electronic address: kenneth.chen@singhealth.com.sg.

PMID: 37730526
DOI: 10.1016/j.euo.2023.09.002

Abstract

Context: Patients with clinically lymph node-positive (cN1) prostate cancer (PCa) are traditionally regarded to have metastatic disease, and the role of local therapy (LT) in their treatment remains unclear.

Objective: To evaluate the outcomes of cN1 PCa patients treated with LT, and secondarily to compare between different modalities of LT, including radiotherapy (RT) and radical prostatectomy (RP).

Evidence acquisition: A bibliographic search was performed using Medline, Embase, and the Cochrane Library to identify studies comparing the survival outcomes of cN1 PCa patients treated with LT (RT or RP) with those who did not receive any form of LT (observation or androgen deprivation therapy alone). The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations were followed. Survival outcomes of the addition of LT were assessed using a random-effect model.

Evidence synthesis: A total of 8522 patients across eight studies were included. LT significantly improved overall survival (OS) across all time points from 2 to 10 yr compared with patients without LT, most notably providing a durable benefit in 10-yr OS (odds ratio [OR]: 1.49, 95% confidence interval [CI] 1.06-2.10). Both RT and RP were associated with benefits to both OS and recurrence-free survival, with no significant difference in OS between both modalities in medium-term follow-up (4-yr OR: 0.76, 95% CI 0.41-1.40, p = 0.19).

Conclusions: Regardless of modality, the use of LT in cN1 patients improved OS. Future studies should aim to identify patients who could benefit from LT and include more comprehensive survival data including biochemical recurrence.

Patient summary: In this study, we evaluated the outcomes of clinically lymph node-positive (cN1) prostate cancer (PCa) patients treated with local therapy (LT) and compared between different modalities of LT, including radiotherapy (RT) and radical prostatectomy (RP). We found that the addition of LT for cN1 PCa patients leads to a significant improvement in survival outcomes, most notably for overall survival, with no significant difference between RT and RP.

Keywords: Lymph nodes; Node-positive disease; Prostate cancer; Radical prostatectomy; Radiotherapy; cN1.

Publication types

Review